Cargando…

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

GSK3640254 is a next‐generation maturation inhibitor with demonstrated potency across HIV‐1 subtypes and a high barrier to emergent resistance. This phase I, 2‐part, randomized, open‐label study (ClinicalTrials.gov identifier, NCT04263142) in healthy participants assessed the relative bioavailabilit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Mark, Pene Dumitrescu, Teodora, Joshi, Samit R., Mathew, Ashwin, Bainbridge, Veronica, Zhan, Joyce, Lataillade, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306620/ https://www.ncbi.nlm.nih.gov/pubmed/34995417 http://dx.doi.org/10.1002/cpdd.1051

Ejemplares similares

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
por: Zhang, Ying, et al.
Publicado: (2023)

Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254( )
por: Spinner, Christoph D, et al.
Publicado: (2022)

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
por: Joshi, Samit R., et al.
Publicado: (2020)

GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile
por: Dicker, Ira, et al.
Publicado: (2022)

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
por: Morales-Ramirez, Javier, et al.
Publicado: (2018)

Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254)
por: Stamatopoulos, Konstantinos, et al.
Publicado: (2023)

Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
por: Dicker, Ira, et al.
Publicado: (2019)

Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian
por: Kanefendt, Friederike, et al.
Publicado: (2022)

Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study
por: Johnson, Elizabeth J., et al.
Publicado: (2014)

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
por: Chen, Yu-Luan, et al.
Publicado: (2023)

Levothyroxine Tablet Malabsorption Associated with Gastroparesis Corrected with Gelatin Capsule Formulation
por: Reardon, David P., et al.
Publicado: (2016)

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
por: Badawi, Mohamed, et al.
Publicado: (2022)

Formulation Development of Albendazole-Loaded Self-Microemulsifying Chewable Tablets to Enhance Dissolution and Bioavailability
por: Sawatdee, Somchai, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome
por: Yang, Shuying, et al.
Publicado: (2016)

Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine
por: Dumitrescu, Teodora Pene, et al.
Publicado: (2019)

Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator‐Formulated Itraconazole Capsules and Solution in Healthy Dogs
por: Hasbach, A.E., et al.
Publicado: (2017)

Engineering of solidified glyburide nanocrystals for tablet formulation via loading of carriers: downstream processing, characterization, and bioavailability
por: Ali, Hany S M, et al.
Publicado: (2019)

Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo‐ and Racemic Praziquantel: Two Phase I Studies
por: Bagchus, Wilhelmina Maria, et al.
Publicado: (2018)

Formulation of Aceclofenac Tablets Using Nanosuspension as Granulating Agent: An Attempt to Enhance Dissolution Rate and Oral Bioavailability
por: Rahim, Haroon, et al.
Publicado: (2020)

Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study
por: Nomoto, Masahiro, et al.
Publicado: (2020)

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
por: Scheidel, Bernhard, et al.
Publicado: (2017)

Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl
por: El Nabarawi, Mohamed A, et al.
Publicado: (2017)

Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization
por: M. Tawfeek, Hesham, et al.
Publicado: (2020)

Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers
por: Min, Mi-Hong, et al.
Publicado: (2019)

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers
por: Miller, Bruce E., et al.
Publicado: (2014)

Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product
por: Minzi, Omary MS, et al.
Publicado: (2013)

Development of Abiraterone Acetate Nanocrystal Tablets to Enhance Oral Bioavailability: Formulation Optimization, Characterization, In Vitro Dissolution and Pharmacokinetic Evaluation
por: Liu, Yuanfen, et al.
Publicado: (2022)

Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
por: Kukulka, Michael, et al.
Publicado: (2016)

Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers*
por: Nahum, Méndez-Sánchez, et al.
Publicado: (2019)

In vivo bioavailability studies of sumatriptan succinate buccal tablets
por: Shivanand, K, et al.
Publicado: (2011)

Correction to: Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers*
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2019)

Correction to: Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers*
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2021)

Formulation and evaluation of transparent ibuprofen soft gelatin capsule
por: Lodha, A., et al.
Publicado: (2012)

Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2022)

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
por: van Rossem, Koen, et al.
Publicado: (2013)

A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2022)

New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients
por: Kim, Yu Kyong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b89pmgmlib22694rd32342vpt0